Abstract Number: PB1913
Meeting: ISTH 2020 Congress
Background: The presence of antiphospholipid autoantibodies (aPL) is mandatory for the diagnosis of antiphospholipid syndrome (APS) but not sufficient to predict the risk of APS-related thrombosis. The identification of additional biomarkers is warranted and microRNAs, which are small non-coding simple chair RNA molecules, may play a role in this context.
Aims: The aim of this study was to determine microRNAs differentially expressed in thrombotic primary APS (t-PAPS) in comparison with controls and to evaluate to discriminate capacity of these microRNAs.
Methods: In this exploratory study, patients and controls were enrolled at the Hematology Center at University of Campinas, Brazil. Differentially expressed miRNAs were identified by MicroArray analysis in Affymetrix workstation. Cut-off values were determined by specificity and sensitivity analysis. A prediction model was built with the most differentially expressed microRNAs between t-PAPS and controls. The discriminate capacity of the model was tested using Receiver-Operating Characteristic test (ROC).
Results: 21 t-PAPS and 21 controls we included. The mean age was 40 (SD 12) in controls and 37 (SD 13) in patients, 52% of patients and controls were women and cardiovascular risk factors were more prevalent among t-PAPS (43% versus 10%). Clinical and laboratory features of t-PAPS are shown in Table 1. From the 24 miRNAs differentially expressed between the two groups, 5 were selected to compose the prediction model. The Beta regression coefficients were 0.227 for hsa-miR-149-3p; 3.536 for hsa-miR-1273g-3p; -1.252 for hsa-miR-4687-3p; 2.968 for hsa-miR-4497 and 1.848 for hsa-miR-4516. The area under the curve was 0.933 (95% IC 0.854-1.000) for the model, as shown in Figure 1.
Conclusions: We identified a cluster of 5 miRNAs with discriminatory ability to identify t-PAPS in relation to controls. This study demonstrates that miRNAs have potential role as biomarkers for t-PAPS. However, the results must be validated in a larger and external population.
|Age in the diagnosis, mean (standard deviation)||33 (16)|
|Non-provoked thrombosis,n (%)||15 (71,4)|
|Venous thrombosis, n (%)||11 (52,4)|
|Multiple thrombosis, n (%)||6 (28,6)|
|Time elapsed since the last thrombosis in months, mean (standard deviation)||34.3 (28.4)|
|Lupus anticoagulante, n (%)||21 (100,0)|
|Anticardiolipin antibody IgM (%)||3 (14,3)|
|Anticardiolipin antibody IgG (%)||9 (42,8)|
|Anti-β2-glycoprotein I antibody (%)||16 (76,2)|
|Triple positivity for aPL, n (%)||9 (42,8)|
[Table 1. Clinical and laboratory features of t-PAPS n=21]
To cite this abstract in AMA style:Oliveira Vaz C, Vieira Geraldo M, Ferreira Alves L, Nascimento Silva Vasconcelos PE, Aparecida Cursino M, Coelho França Quintanilha J, Brito Bastos L, Tripiquia Vechiatto Mesquita GL, Cardoso Jacintho B, Rosa dos Santos AP, Godoy Torso N, Marques de Oliveira J, Sereno Cobaxo T, Aparecido Geraldo A, Bassani Borges J, Costa de Freitas RC, Annichino-Bizzacchi JM, Moraes Mazetto B, Moriel P, Loureiro de Andrade Orsi F. MicroRNAs as Potential Biomarkers in Thrombotic Primary Antiphospholipid Syndrome [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/micrornas-as-potential-biomarkers-in-thrombotic-primary-antiphospholipid-syndrome/. Accessed December 6, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/micrornas-as-potential-biomarkers-in-thrombotic-primary-antiphospholipid-syndrome/